1 / 32

MANNOSE-BINDING LECTIN PATHWAY

MANNOSE-BINDING LECTIN PATHWAY. Gary C. Pien, MD/PhD Division of Allergy/Immunology Children’s Hospital of Philadelphia 34 th St and Civic Center Blvd Philadelphia, PA 19104. COMPLEMENT ACTIVATION PATHWAYS. Janeway, C, et al, Immunobiology , New York: Garland Science, 2005.

ugo
Download Presentation

MANNOSE-BINDING LECTIN PATHWAY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MANNOSE-BINDING LECTIN PATHWAY Gary C. Pien, MD/PhD Division of Allergy/Immunology Children’s Hospital of Philadelphia 34th St and Civic Center Blvd Philadelphia, PA 19104

  2. COMPLEMENT ACTIVATION PATHWAYS Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  3. MANNOSE-BINDING LECTIN (MBL) • pattern recognition receptor • recognizes pathogen-associated molecular patterns (PAMPs) • member of collectin sub-family of C-type lectins, such as surfactants A/D • serum protein • synthesized primarily in liver • “acute phase reactant” • rises up to 3x in 1-2 weeks • multimers of homotrimers • collagen-like helix domain (stalk) • -helical coiled coil (neck) • carbohydrate-recognition domain (CRD) • structurally homologous to C1q Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  4. MBL STRUCTURE AND FUNCTION • binding sites recognize D-mannose, L-fucose, N-acetylglucosamine • binding sites have fixed orientation and spacing (45 Å) • ligands must have correct orientation and spacing • provides “antigen specificity” • structures “found only on microbes and not on host cells” – overstated? Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  5. MBL LIGANDS Worthley, DL, et al, 2006, World J Gastroenterol 12:6420; Takashi, K, et al, 2006, Curr Opin Immunol 18:16.

  6. MBL OPSONIZATION • MBL pathway homologous to classical complement pathway • acts as an “ante-antibody” • MBL binds target carbohydrates on microbial surfaces • recruits MBL-associated serine proteases (MASPs) to site • MBL:MASP complex activates complement, leading to downstream anti-microbial functions Takashi, K, et al, 2006, Curr Opin Immunol 18:16.

  7. MASPs – 2 GENES, 4 PRODUCTS • MASP1 • can cleave C2, somewhat C3 • function unknown • MASP3 • alternative splice product of MASP1 gene • lacks serine protease domain • function unknown • MASP2 • minimal functional unit = MASP2 homodimer + two MBL homotrimers • cleaves C4 and C2 to generate C3 convertase (C4bC2b) • MAp19 • alternative splice product of MASP2 gene • function unknown Sorensen R, et al, 2005, Springer Semin Immunopathol 27:299.

  8. MBL:MASP “TULIPS” • MASPs are predominantly synthesized in liver • form Ca+2-dependent homodimers • unknown why heterodimers do not occur • MASP1 and MAp19 associate with low oligomers of MBL • MASP3 and MASP2 associate with higher order oligomers • MASPs can also associate with ficolins (another group of PAMP binders) • binding of MBL:MASP complex to ligand activates serine protease • unclear mechanism for how this occurs Sorensen R, et al, 2005, Springer Semin Immunopathol 27:299; Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  9. COMPLEMENT ACTIVATION • activated MBL:MASP cleaves C4, C2 to form C3 convertase • C3 convertase is bound to surface of pathogen • cleaves other factors to produce effector functions Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  10. MEMBRANE-ATTACK COMPLEX C5b, C6, C7, C8, C9 Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  11. AGE AND MBL LEVELS • at birth, MBL level is 2/3 of adult concentration • adult level reached at 1 month of age • small decline in levels through adulthood Ip WK, et al, 2004, Scand J Immunol 59:310.

  12. GENETIC VARIATION • MBL encoded by MBL2 gene • MBL1 pseudogene • both closely positioned on chromosome 10 • exons 1-2 encode Gly-Xaa-Yaa triple collagen helix motif to form stalk • exon 3 encodes coiled-coil neck • exon 4 encodes CRD domain • polymorphisms exist in exon 1 that affect MBL serum levels • promoter polymorphisms also exist that affect expression levels Garred, P, et al, 2006, Genes and Immunity 7:85.

  13. GENETIC VARIATION • A is normal allele  A/A is normal haplotype • B, C, and D are variant alleles • O indicates any of the variant alleles • serum MBL levels correlate with haplotype • however, people with same genotype may differ in MBL levels by 10x Garred, P, et al, 2006, Genes and Immunity 7:85; Worthley, DL, et al, 2006, World J Gastroenterol 12:6420

  14. GENETIC VARIATION • promoter polymorphisms at 3 distinct locations: H/L, X/Y, P/Q • 7 possible MBL haplotypes  28 possible genotypes (diploid) • HYPA • LYPA • LYQA • LXPA • HYPD • LYPB • LYQC Garred, P, et al, 2006, Genes and Immunity 7:85; Thiel, S, et al, 2006, Mol Immunol 43:86;Kilpatrick, DC, Biochimica 2002, 1572:401.

  15. GENETIC VARIATION • promoter polymorphisms at 3 distinct locations: H/L, X/Y, P/Q • 7 possible MBL haplotypes  28 possible genotypes (diploid) Dommett, RM, et al, 2006, Tissue Antigens 68:193.

  16. GENETIC VARIATION • variant MBL alleles have alterations in collagen helix stalk • impaired multimerization • forms low-order oligomers • oligomers have preference for MASP1 and MAp19 … cascade failure? • non-functional and unstable Eisen, DP and Minchinton RM, 2003, Clin Inf Dis 37:1496.

  17. MBL LEVELS CORRELATE WITH ACTIVITY • MBL concentration affects activity of complex and C4b deposition Worthley, DL, et al, 2006, World J Gastroenterol 12:6420

  18. MBL DEFICIENCY AND DISEASE ASSOCIATIONS • MBL linked to human disease based on case report in 1968 • female patient with recurrent URI and diarrhea in childhood • no apparent immunodeficiency • neutrophils cultured in patient’s serum could not phagocytose yeast • low C3 deposition but normal complement function • “common opsonic defect” with impaired complement deposition • defect found in 5-8% of health population • separately, group purified a protein from rabbit liver using yeast mannan • protein could activate complement when bound to mannan surfaces • led to identification of MBL Garred, P, et al, 2006, Genes and Immunity 7:85.

  19. MBL DEFICIENCY AND DISEASE ASSOCIATIONS • what is a physiologically “low” level? • ranges from 5 – 10,000 ng/ml in population • no individual completely deficient in MBL has been reported • 30% of population has level < 500 ng/ml • 10-20% have levels < 100 ng/ml • 50-100 ng/ml has been labeled “severe MBL deficiency” • majority of individuals with low MBL are healthy • difficult to link MBL deficiency with infection susceptibility • infants have recurrent respiratory infections, OM, chronic diarrhea • MBL important when maternally acquired antibodies wane and host responses still maturing? • clinical significance likely varies depending on disease context • disease susceptibility modifier? Garred, P, et al, 2006, Genes and Immunity 7:85.

  20. MBL DEFICIENCY AND INFECTIONS Eisen, DP and Minchinton RM, 2003, Clin Inf Dis 37:1496.

  21. MBL DEFICIENCY AND INFECTIONS Eisen, DP and Minchinton RM, 2003, Clin Inf Dis 37:1496.

  22. MBL DEFICIENCY AND INFECTIONS Eisen, DP and Minchinton RM, 2003, Clin Inf Dis 37:1496.

  23. MBL DEFICIENCY AND DISEASE ASSOCIATIONS • chemotherapy patients • children with ALL and variant MBL had twice as many days of F&N • adults who developed bacteremia or pneumonia after chemotherapy had lower levels of MBL than those who did not • low MBL associated with increased rates of severe infections and F&N in adult cancer patients • allogeneic hematopoietic stem cell transplant patients • invasive infections occurred more frequently in patients with variant MBL alleles Thiel, S, et al, 2006, Mol Immunol 43:86.

  24. MBL DEFICIENCY AND DISEASE ASSOCIATIONS • SIRS / sepsis / MOD • adults who died in ICU from sepsis/MOD had 3x lower MBL levels • adults with variant MBL genotypes had higher risk of sepsis Thiel, S, et al, 2006, Mol Immunol 43:86; Klein, NJ, 2005, Mol Immunol 42:919.

  25. MBL DEFICIENCY AND DISEASE ASSOCIATIONS • autoimmunity • low MBL levels linked to worse prognosis in RA • low MBL predisposes to SLE • low MBL strongly associated with more severe celiac disease • vascular disease • higher frequency of MBL mutations in patients with Kawasaki disease • higher risk of MI in patients with low MBL levels • obstetrics • couples with recurrent spontaneous abortion had higher frequency of MBL deficiency in both partners • other studies only found association with maternal deficiency Thiel, S, et al, 2006, Mol Immunol 43:86.

  26. MASP DEFICIENCY • patient with MASP2 deficiency • healthy until age 13 • developed UC • erythema multiforme bullosum • SLE? • 3 episodes of severe pneumococcal pneumonia • progressive lung fibrosis • hypocomplementemia • homozygous D105G mutation in MASP2 • other family members healthy • had low activity levels in MBL pathway • were heterozygous for MASP2 mutation Stengaard-Pedersen, K, et al, 2003, NEJM 349:554.

  27. MASP DEFICIENCY • 10% of general (Danish) population is heterozygous for D105G mutation (492 pts) • 50% of normal circulating MASP2 levels (heterozygotes ~ 200 ng/ml) • individuals who are homozygous expected at 1:1000 • have only 10% of normal circulating MASP2 levels (~ 50-75 ng/ml) • no Hong Kong Chinese carried D105G mutation (573 pts) • did find another deficiency-associated mutation, rare frequency Kilpatrick, DC, Biochimica et Biophysica Acta 2002, 1572:401; Sorensen R, et al, 2005, Springer Semin Immunopathol 27:299.

  28. COMPLEMENT DEFICIENCIES - KATE http://www.clinimmsoc.org/teaching/tips/complement_deficiencies.pdf

  29. PATHWAY DEFECTS AND HUMAN DISEASE Janeway, C, et al, Immunobiology, New York: Garland Science, 2005.

  30. MBL PATHWAY TESTING • IBT Laboratories (www.ibtreflab.com) • MBL protein • sandwich ELISA • uses monoclonal antibody against oligomeric CRD • define normal > 100 ng/ml • MBL pathway function test • ELISA C4b deposition assay • functional assay of initial pathway (MBL, MASP) • ProGenotyper MBL panel • rtPCR for MBL variant alleles • ProGenotyper MASP2 polymorphisms • DNA sequencing (D105G or entire gene?)

  31. MBL REPLACEMENT THERAPY • NatImmune A/S (www.natimmune.com) • Danish biotech company • developed rhMBL • Phase I clinical trial in 2004 • infused rhMBL into healthy subjects • no significant adverse events • serum t½ = 30 hours • Enzon Pharmaceuticals (www.enzon.com) • US biotech company licensed rhMBL from NatImmune in 2005 • Phase I/II clinical trials • rhMBL prophylaxis and treatment • oncology and liver transplant patients • reduce risk of infection

  32. CONCLUSIONS • MBL pathway involved in host defense and possibly other functions • MBL deficiency alone not clearly associated with infection risk • deficiency most clearly associated with increased infection risk in immunosuppressed/co-existing immunodeficient patients • deficiency may predispose to infections in infancy/early childhood • low MBL may be susceptibility risk factor for other diseases • MASP2 deficiency has been associated with recurrent infections • n = 1 (maybe 2) • MASP2 may have other functions outside of MBL pathway (ficolins) • MASP2 deficiency may have more prominent phenotype than MBL deficiency

More Related